Title |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
|
---|---|
Published in |
Cancer Chemotherapy and Pharmacology, March 2010
|
DOI | 10.1007/s00280-010-1282-4 |
Pubmed ID | |
Authors |
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, Laetitia Dahan, Danielle Bagarry-Liegey, Caroline Brunet, Arthur Varoquaux, Nicolas Frances, Hafedh Marouani, Antoine Giovanni, Rose-Marie Ferri-Dessens, Mohamed Chefrour, Roger Favre, Florence Duffaud, Jean-François Seitz, Michel Zanaret, Bruno Lacarelle, Cédric Mercier |
Abstract |
Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed a simple, rapid, and inexpensive functional testing for DPD activity, as a means to identify deficient patients and to anticipate subsequent 5-FU-related toxicities. We present here the impact of fluoropyrimidine dose tailoring based on DPD functional screening in a prospective, open, non-controlled study, both in term of reduction in severe toxicities and of treatment efficacy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 2 | 3% |
Japan | 1 | 1% |
China | 1 | 1% |
United States | 1 | 1% |
Unknown | 75 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 15% |
Student > Ph. D. Student | 10 | 13% |
Researcher | 9 | 11% |
Other | 9 | 11% |
Professor | 7 | 9% |
Other | 19 | 24% |
Unknown | 14 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 40% |
Agricultural and Biological Sciences | 13 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 13% |
Biochemistry, Genetics and Molecular Biology | 6 | 8% |
Mathematics | 1 | 1% |
Other | 4 | 5% |
Unknown | 14 | 18% |